Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEL | P19835 | 4/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23536072 | 0.91 | GPR84 (0.40) | MAOBTDP1 | |
| SCHEMBL12453115 | 0.83 | DAO (0.43) | CELDAOATMKMT2AMAOB | |
| SCHEMBL12453121 | 0.83 | KMT2A (0.44) | KMT2AMEN1 | |
| SCHEMBL16503442 | 0.83 | LTA4H (0.41) | CELKMT2AMEN1TDP1 | |
| SCHEMBL7735405 | 0.81 | DAO (0.41) | DAOATMKMT2AMAOBMEN1 | |
| SCHEMBL27858590 | 0.81 | EPHX2 (0.48) | MAOBUSP2 | |
| SCHEMBL20573232 | 0.78 | MAOB (0.40) | DAOMAOB | |
| SCHEMBL26038271 | 0.78 | CA2 (0.55) | ATM | |
| SCHEMBL6129078 | 0.78 | CA1 (0.49) | ATMKMT2AMEN1USP2CYP3A4 | |
| SCHEMBL12453144 | 0.77 | MMP1 (0.37) | CELDAOPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| EP-2454216-A1 | NON-POLAR AND POLAR LEAVING GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| CN-102471176-A | Non-polar and polar leaving groups | BAYER SCHERING PHARMA AG | 2012-05-23 | — | — | CN | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | PGLS, RABGGTB, LNPEP | CEL 129/4885DAO 1137/4885ATM 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.